Entero Healthcare Solutions has announced significant strategic moves that are set to reshape its business portfolio. The company's board of directors has approved two major transactions: the complete divestment of its subsidiary Suprabhat Pharmaceutical Private Limited and the acquisition of a majority stake in Ace Cardiopathy Solutions Private Limited.

Divestment of Suprabhat Pharmaceutical

In a board meeting held on September 29, 2025, Entero Healthcare Solutions approved the sale of its entire 100% stake in Suprabhat Pharmaceutical Private Limited. The company has entered into a Share Purchase Agreement (SPA) for this transaction on the same day.

Key details of the divestment include:

• Buyers: Mr. Yash Sudhir Biradar and Ms. Kavita Sudhir Biradar, who were the erstwhile promoters of Suprabhat Pharmaceutical.
• Consideration: The sale is expected to fetch up to INR 37,00,000.
• Completion Timeline: The divestment is anticipated to be completed during the financial year 2025-26.

It's worth noting that Suprabhat Pharmaceutical contributed marginally to Entero's consolidated financials in the last fiscal year:

Acquisition of Ace Cardiopathy Solutions

In a strategic move to expand its presence in the medical devices distribution sector, Entero Healthcare Solutions has also approved the acquisition of a 60% stake in Ace Cardiopathy Solutions Private Limited.

Highlights of the proposed acquisition:

• Target Company: Ace Cardiopathy Solutions Private Limited, incorporated on December 1, 2009, in Delhi, India.
• Business Profile: Wholesale distribution of medical devices and other healthcare and allied products.
• Acquisition Cost: The deal is valued between INR 59.30 crore to INR 77.10 crore, subject to adjustments for net debt, normalized working capital, and achievement of certain conditions.
• Completion Timeline: The acquisition is expected to be finalized by January 31, 2026.

Ace Cardiopathy has shown consistent revenue performance over the past three fiscal years:

*Unaudited figures

Strategic Implications

These transactions represent significant portfolio restructuring for Entero Healthcare Solutions. By divesting Suprabhat Pharmaceutical, which had a minimal contribution to the company's financials, Entero appears to be streamlining its operations. Simultaneously, the acquisition of a majority stake in Ace Cardiopathy Solutions aligns with Entero's core business of wholesale distribution in the healthcare sector and could potentially boost its market presence in the medical devices segment.

The company's Vice President - General Counsel, Company Secretary & Compliance Officer, Sanu Kapoor, confirmed that these decisions were made in compliance with SEBI regulations and have been duly reported to the stock exchanges.

Entero Healthcare Solutions , acting on behalf of the Government of Singapore (GOS), has further reduced its stake in Entero Healthcare Solutions Limited through a recent open market transaction. The move continues the gradual reduction of GIC's position in the company since February 2024.

Transaction Details

On August 11, 2025, GIC sold 9,846 equity shares of Entero Healthcare Solutions Limited. This sale resulted in a decrease in GIC's shareholding from 3.16% to 3.14% of the company's total share capital.

Shareholding Impact

The transaction has slightly altered GIC's position in Entero Healthcare Solutions:

Company Overview

Entero Healthcare Solutions Limited is listed on both the National Stock Exchange of India Limited and BSE Limited. The company's total equity share capital stands at 43,508,907 shares, as per the shareholding pattern dated June 30, 2025.

Historical Context

GIC's involvement with Entero Healthcare Solutions has seen significant changes over time:

• As of February 29, 2024, GIC held a 5.16% stake in the company, amounting to 2,243,457 equity shares.
• Since then, GIC has been gradually reducing its position through multiple transactions.
• The current disclosure was triggered as the cumulative sales reached a reportable threshold under Regulation 29(2) of the SEBI Takeover Regulations.

Regulatory Compliance

The disclosure of this transaction was made in compliance with the Securities and Exchange Board of India (Substantial Acquisition of Shares and Takeovers) Regulations, 2011. GIC Private Limited, as an investment manager acting on behalf of the Government of Singapore, has the power to exercise voting rights for all the shares it manages.

This latest transaction underscores the ongoing adjustments in GIC's investment portfolio, reflecting its dynamic approach to managing holdings in the Indian healthcare sector.